Full Press Release Details
Adagio Medical Unveils Preliminary Acute Results
from FULCRUM-VT U.S. Pivotal Study in Late Breaking Session at VT Symposium
97% Acute Effectiveness and Favorable Safety
Results from Proprietary ULTC for Ventricular Tachycardia
LAGUNA HILLS, CA, October 10, 2025 - Adagio Medical
Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies
for the treatment of cardiac arrhythmias, today announced preliminary acute (within 7 days) safety and efficacy results from the
Adagio's FULCRUM-VT Study evaluating Ultralow Temperature Cryoablation ("ULTC") for the treatment of Sustained Monomorphic
Ventricular Tachycardia ("SMVT") in patients with both ischemic and nonischemic cardiomyopathy. The data are being presented
by Travis Richardson, MD, Assistant Professor of Medicine, Clinical Cardiac Electrophysiology, Vanderbilt University Medical Center, in
a Late Breaking Clinical Trials Session at the 20th Annual International Symposium on Ventricular Arrhythmias being held
in Philadelphia on October 10, 2025.
A total of 207 patients underwent ventricular tachycardia ("VT")
ablation using Adagio's ULTC system at 19 sites in the United States and Canada. The study included patients with both ischemic
("ICM") and non-ischemic ("NICM") cardiomyopathies (LVEF=35+/-10%, 33% NICM, 75% with congestive heart failure).
Mean procedure duration was 206+/- 68 minutes and acute clinical success, defined as non-inducibility of target ventricular arrhythmias,
was 97.4%, with all clinically-relevant ventricular tachycardias eliminated in 96.7% of patients tested by post-ablation programmed electrical
stimulation. Key safety findings included a 2.5% rate of major adverse events including four (1.9%) peri-procedural deaths, of which one
(0.5%) was adjudicated by an independent clinical events committee as definitely related to the investigational device.
A presentation with additional details and accompanying figures are
available on a Current Report on Form 8-K, which is being filed concurrently with this press release and available on the SEC's
website at www.sec.gov.
"The patient profile in FULCRUM-VT is representative of what
we see in real-world practice. The ability of Adagio's ULTC system to produce deep, titratable endocardial lesions without irrigation
and without concerns for catheter stability make it a promising tool for a broad patient population. These factors, along with the broad
inclusion criteria for the study, fueled swift enrollment," said Dr. Richardson. "FULCRUM-VT not only included patients
with ischemic myopathy, but also a large number with nonischemic disease, whose VT is often more difficult to treat due to deep substrate.
Despite this, the acute effectiveness across the study population was excellent. This, along with the favorable safety profile of the
ULTC System, is encouraging. VT is a largely undertreated condition, partially because the available treatment tools make ablation procedures
challenging, and I have hope that ULTC will help to change that. We look forward to the six-month primary efficacy endpoint results
of the FULCRUM-VT trial, which the company currently plans to share at the Heart Rhythm 2026 conference."
The FULCRUM-VT Study is a prospective, multi-center investigation of
ULTC evaluating acute safety and effectiveness in patients with scar-related VT refractory to antiarrhythmic drug therapy and a left ventricular
ejection fraction greater than 20%. Long-term outcomes as well as analysis of the effectiveness in different myocardial substrates will
be reported in the future.
"We are pleased with the preliminary FULCRUM-VT acute data, which
highlight the potential of Adagio's proprietary ULTC technology to transform treatment for patients with ventricular tachycardia,"
said Todd Usen, Chief Executive Officer of Adagio Medical. "On behalf of the entire Adagio Medical team, I want to thank all
of the investigators, research coordinators and patients who have supported this study and whose commitment to serving this underserved
population of patients will bring us one step closer to a purpose-built solution for VT. We thank the VT Symposium for this opportunity
to share our results as part of a Late Breaking Session in Philadelphia."
About Adagio Medical Holdings, Inc.
Adagio is a medical device company focused on developing and commercializing
products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation
(ULTC) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac
tissue. The Company is currently focused on the treatment of ventricular tachycardia (VT) with its purpose-built vCLAS Cryoablation
System, which is CE Marked and is currently under evaluation in the Company's FULCRUM-VT U.S. IDE Pivotal Study.
FULCRUM-VT (Feasibility of Ultra-Low
Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm study,
enrolling 206 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation
of drug refractory VT in accordance with current treatment guidelines. The results of the study will be used to apply for FDA premarket
approval (PMA) for Adagio's vCLAS Cryoablation System, potentially leading to the broadest industry indication for purely
endocardial ablation of scar-mediated VT.
Adagio's vCLAS Cryoablation
System is commercially available for the treatment of monomorphic ventricular tachycardia in Europe and select other geographies but is
limited to investigational use in the United States.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects,"
"intends," "projects," "plans," and "future" or similar expressions are intended to identify
forward-looking statements. Forward-looking statements include statements concerning: the reproducibility of any favorable results initially
seen in Adagio's preliminary FULCRUM-VT acute data; the ability of Adagio's proprietary ULTC system to become a tool for a
broad patient population; Adagio's research, development and regulatory plans for its product candidates; and the ability of Adagio's
proprietary ULTC technology to transform treatment for patients with VT. Forward-looking statements are based on management's current
expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from
those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees
of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Adagio's
business are described in detail in Adagio's Securities and Exchange Commission ("SEC") filings, including in its Annual
Report on Form 10-K for the full-year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended June 30,
2025, which are available on the SEC's website at www.sec.gov. Additional information will be made available in other filings that
Adagio makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Adagio disclaims any
obligation to update these statements except as may be required by law.
Chief Financial Officer and Chief Business Officer